FLOW CYTOMETRY, CD 79A

The Flow Cytometry CD79a Test is a specialized immunophenotyping assay used to detect and evaluate the expression of CD79a, an important component of the B-cell receptor complex. CD79a is considered a highly sensitive marker of B-cell lineage and is expressed throughout most stages of B-cell development, including precursor and mature B lymphocytes.

Flow cytometry technology enables rapid and accurate analysis of thousands of cells individually, allowing identification of CD79a-positive cell populations and assessment of their immunophenotypic characteristics. CD79a is commonly included in comprehensive leukemia and lymphoma panels to help determine whether abnormal cells originate from the B-cell lineage.

The test is particularly valuable in the diagnosis and classification of B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell lymphomas, and other B-cell lymphoproliferative disorders. Because CD79a may be expressed even in immature B-cell populations, it serves as an important marker when evaluating acute leukemias and distinguishing them from T-cell or myeloid malignancies.

Benefits of the Test

• Identifies B-cell lineage cells
• Assists in leukemia and lymphoma diagnosis
• Supports classification of B-cell malignancies
• Helps distinguish B-cell disorders from other hematological diseases
• Assists disease monitoring and follow-up
• Provides valuable immunophenotypic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD79a testing for:

• Suspected B-cell Acute Lymphoblastic Leukemia (B-ALL)
• B-cell lymphoma evaluation
• Leukemia immunophenotyping
• Lymphoproliferative disorder investigation
• Bone marrow disorder assessment
• Abnormal lymphocyte population evaluation
• Monitoring hematological malignancies
• Comprehensive flow cytometry analysis

The test helps confirm B-cell origin and contributes to accurate disease classification.

Preparation Before Test

The test may require:

• Peripheral blood sample
• Bone marrow aspirate
• Lymph node tissue
• Body fluid specimen
• Other clinically appropriate samples

Preparation generally includes:

• No fasting is required
• Inform your physician about current medications
• Follow laboratory collection instructions

The sample is processed using advanced multiparameter flow cytometry techniques.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and panel complexity.

Who Should Take This Test?

• Patients with suspected leukemia
• Individuals with suspected lymphoma
• Patients undergoing bone marrow evaluation
• Individuals with abnormal lymphocyte counts
• Patients requiring immunophenotyping studies
• Individuals referred by hematologists or oncologists

Flow Cytometry CD79a testing is an important component of modern hematological diagnostics and B-cell lineage assessment.

Clinical Significance

CD79a expression may be observed in:

• B-cell Acute Lymphoblastic Leukemia (B-ALL)
• Mature B-cell Neoplasms
• Non-Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia (CLL)
• B-cell Lymphoproliferative Disorders
• Normal B Lymphocytes
• Plasma Cell Disorders (in selected settings)

Detection of CD79a-positive cells helps establish B-cell lineage and contributes to the accurate classification of hematological malignancies.

Important Note

CD79a is usually interpreted together with other B-cell markers such as CD19, CD20, CD22, CD10, CD34, CD45, Kappa Light Chains, and Lambda Light Chains. Comprehensive interpretation by a hematopathologist is essential for accurate diagnosis and treatment planning.